Brain tumor imaging in clinical trials

American Journal of Neuroradiology

Volumn 29, Issue 3, 2008, Pages 419-424

  Henson, John W ^a,b   Ulmer, S ^a   Harris, G J ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM;

BRAIN TUMOR; CLINICAL PROTOCOL; COMPUTER ASSISTED RADIOGRAPHY; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; IMAGE ENHANCEMENT; MEASUREMENT; NEUROIMAGING; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; REVIEW; SOLID TUMOR; STANDARDIZATION; TREATMENT RESPONSE; TUMOR VOLUME; VALIDITY; WORLD HEALTH ORGANIZATION;

ALGORITHMS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; DIAGNOSTIC IMAGING; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL;

EID: 41149091796     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: 10.3174/ajnr.A0963     Document Type: Review

References (20)

1. Batchelor T, Stanley K, Andersen J. Clinical trials in neuro-oncology. Curr Opin Neurol 2001;14:689-94
2. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-14
3. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16
4. Macdonald DR, Cascino TL, Schold SC, et al. Response criteria for phase II studies of malignant glioma. J Clin Oncol 1990;8:1277-80
5. Galanis E, Buckner JC, Maurer MJ, et al. Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods. Neuro Oncol 2006;8:156-65
6. Hess KR, Wong ET, Jaeckle KA, et al. Response and progression in recurrent malignant glioma. Neuro Oncol 1999;1:282-88
7. Shah GD, Kesari S, Xu R, et al. Comparison of linear and volumetric criteria in assessing tumorresponse in adult high-grade gliomas. Neuro Oncol 2006;8:38-46
8. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10
9. Sorensen AG, Patel S, Harmath C, et al. Comparison of diameter and perimeter methods for tumor volume calculation. J Clin Oncol 2001;19:551-57
10. Warren KE, Patronas N, Aikin AA, et al. Comparison of one-, two-, and three-dimensional measurements of childhood brain tumors. J Natl Cancer Inst 2001;93:1401-05
11. Ulmer S, Mavrakis A, Barker FG, et al. Incidence of multifocal lesions in malignant glioma as detected by MRI. Neurology 2006;66:A431
12. Forsyth PA, Petrov E, Mahallati H, et al. Prospective study of postoperative magnetic resonance imaging in patients with malignant gliomas. J Clin Oncol 1997;15:2076-81
13. Ulmer S, Braga TA, Barker FG, et al. Clinical and radiographic features of peritumoral infarction following resection of glioblastoma. Neurology 2006;67:1668-70
14. Smith JS, Cha S, Mayo MC, et al. Serial diffusion-weightedmagnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury. J Neurosurg 2005;103:428-38
15. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-79
16. Prados MD, Seiferheld W, Sandler HM, et al. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. Int J Radiat Oncol Biol Phys 2004;58:1147-52
17. Grant R, Liang BC, Slattery J, et al. Chemotherapy response criteria in malignant glioma. Neurology 1997;48:1336-40
18. Ballman KV, Buckner JC, Brown PD, et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol 2007;9:29-38
19. Pope WB, Lai A, Nghiemphu P, et al. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006;66:1258-60
20. Mills SJ, Patankar TA, Haroon HA, et al. Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? AJNR Am J Neuroradiol 2006;27:853-58